Systemic Therapy in BRAF V600E-Mutant Metastatic Colorectal Cancer: Recent Advances and Future Strategies

AbstractPurpose of ReviewThis review seeks to detail the clinical and pathologic features specific toBRAFV600E colorectal cancer. Application of novel preclinical findings translated into the clinic for the development of new therapeutic options for patients withBRAFV600E metastatic colorectal cancer will be detailed.Recent FindingsWhile BRAF inhibitors as monotherapy do not have the same clinical activity for colorectal cancer relative to other solid tumors harboring an oncogenicBRAFV600E mutation, combination approaches targeting BRAF + MEK + EGFR hold promise for patients withBRAFV600E colorectal cancer.SummarySimultaneous targeting of multiple drivers along the MAPK pathway improves clinical outcomes for patients withBRAFV600E colorectal cancer. Targeted therapies and immunotherapy hold great promise in the years to come for patients with this subtype of colorectal cancer.
Source: Current Colorectal Cancer Reports - Category: Cancer & Oncology Source Type: research